Research Article Open Access

Anti-β2 Glycoprotein-I Antibody in Acute Myocardial Infarction

Mohammad Shojaei1, Abdolreza Sotoodeh Jahromi2, Hamideh Ebadat3, Seyed Hamid Moosavy4, Bita Seddigh5 and Abdolhossien Madani5
  • 1 Department of Cardiology, Jahrom University of Medical Science, Iran
  • 2 Department of Immunology, Jahrom University of Medical Science, Iran
  • 3 Department of Student Research Committee, Jahrom University of Medical Science, Jahrom, Iran
  • 4 Department of Internal Medicine, Hormozgan University of Medical Science, Iran
  • 5 Department of Epidemiology, Center for Determinants in Health Promotion, Hormozgan University of Medical Science, Bandarabbas, Iran


Problem statement: Ischemic cardiac manifestations have been reported in a various percentage of patients with anti-phospholipid antibodies. Data concerning the relation between anti- Phospholipid (aPL) antibodies and myocardial infarction in subjects without evidence of overt autoimmune disease are conflicting. Anti-beta2 glycoprotein-I (anti-beta2-GPI) antibody is detected in various diseases like rheumatoid arthritis, systemic lupus erythematosus and anti-phospholipid antibody syndrome. The study of anti-beta2-GPI antibody in Acute Myocardial Infarction (AMI) might shed light on etiologic mechanisms in the pathogenesis of acute coronary syndromes. The purpose of the present study was to determine association of plasma aPL antibodies, namely, antibeta2- GPI antibodies, with AMI. This study was designed to investigate whether prevalence of antibeta2- GPI antibodies, in patients who had acute myocardial infarction and to analyze their relationship with traditional cardiovascular risk factors. Approach: We investigated the prevalence of anti-beta2- GPI IgG in a well characterized group of patients with AMI as a case group. Sera from 74 patients with AMI and from 76 healthy subjects, matched for age and sex as a control group. Using ELISA to evaluate the presence of IgG isotype of anti-beta2-GPI autoantibodies in their sera. Results: The prevalence of anti-beta2-GPI IgG in the control group (10.50%) resulted significantly lower than in patients with AMI (37.80%) (p<0.005). There was significant difference between positive anti-β2-GPI test in patients with STEMI and those with NSTEMI (66.7% Vs 36.4%), (p = 0.020). Conclusion: Our findings suggest that anti-beta2-GPI IgG antibodies seemed to behave as independent risk factors for myocardial infarction, which may represent a link between autoimmunity and atherosclerosis in patients with acute myocardial infarction. Further studies with bigger patients are needed to explore association of anti-β2-GPI IgG with STEMI and NSTEMI.

American Journal of Applied Sciences
Volume 8 No. 8, 2011, 758-761


Submitted On: 16 March 2011 Published On: 18 July 2011

How to Cite: Shojaei, M., Jahromi, A. S., Ebadat, H., Moosavy, S. H., Seddigh, B. & Madani, A. (2011). Anti-β2 Glycoprotein-I Antibody in Acute Myocardial Infarction. American Journal of Applied Sciences, 8(8), 758-761.

  • 0 Citations



  • Anti-beta2 glycoprotein-I
  • Acute Myocardial Infarction (AMI)
  • anti-Phospholipid (aPL) antibodies
  • GPI antibodies
  • Anti-Cardiolipin Antibodies (ACA)
  • lupus anticoagulant
  • blood samples
  • control group
  • traditional cardiovascular